Onco-Innovations Secures $5M Private Placement to Advance Cancer Research

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has taken a significant step toward advancing its cancer research initiatives by executing a term sheet for a CAD$5 million non-brokered private placement with arm's-length institutional investors. The announcement, made earlier this week, details a proposed offering of 6,764,070 units at a notional price of CAD$0.7392 per unit, with each unit consisting of one common share and one common share purchase warrant. The transaction is expected to close on or about July 15, 2026, pending customary conditions and regulatory approvals.

The capital raise is strategically aimed at propelling the development of Onco-Innovations' lead ONC010 program, which encompasses manufacturing and preclinical testing activities. Additionally, funds will support the advancement of the company's proprietary SynoGraph(TM) platform and provide general working capital. The structure of the offering involves determining the company's economic interest through 18 monthly settlement tranches based on the future trading price of its shares, with further details to be disclosed upon closing.

Onco-Innovations, a Canadian-based company dedicated to cancer research and treatment, specializes in oncology and holds an exclusive worldwide license to patented technology targeting solid tumours. This funding comes at a crucial time as the company seeks to accelerate its research and development efforts in a highly competitive field. The private placement underscores institutional investors' confidence in Onco-Innovations' pipeline and its potential to deliver innovative cancer therapies.

The impact of this announcement extends beyond the immediate capital infusion. For investors and stakeholders, it signals that Onco-Innovations is progressing toward key milestones, particularly the advancement of its ONC010 program from preclinical to clinical stages. The structured settlement tranches may also provide a mechanism for aligning investor interests with the company's long-term performance. As the company moves forward, the successful closure of this offering could pave the way for further partnerships and research breakthroughs.

For more information about Onco-Innovations and its ongoing projects, visit the company's newsroom at https://ibn.fm/ONNVF.